Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)

NCT07142291 is registered in ClinicalTrials.gov with PhenoNet, Inc. as lead sponsor.

NCT NCT07142291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07142291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
PhenoNet, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 25, 2025
Completion date
June 30, 2027
Enrollment
105 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)